Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
INCY
Incyte Corporation
Incyte's business is centered on oncology-focused therapeutics, including Monjuvi and a broad cancer pipeline.
|
$20.63B |
$105.75
+0.19%
|
|
WST
West Pharmaceutical Services, Inc.
West generates revenue from contract manufacturing services, moving towards higher-margin opportunities.
|
$19.93B |
$277.31
-1.26%
|
|
EXAS
Exact Sciences Corporation
Oncotype DX is a genomic assay used as a companion diagnostic in oncology, and the company discusses companion diagnostic capabilities and leadership in Precision Oncology.
|
$19.21B |
$101.44
+0.31%
|
|
IFF
International Flavors & Fragrances Inc.
DEB and enzyme-based biotechnologies are core to IFF's Health & Biosciences innovation and product offerings.
|
$17.88B |
$69.80
+0.86%
|
|
MEDP
Medpace Holdings, Inc.
Medpace's core business is a specialized full-service CRO delivering Phase I–IV clinical development services.
|
$17.04B |
$606.27
-0.91%
|
|
BWXT
BWX Technologies, Inc.
Radiopharmaceuticals for nuclear medicine imaging and diagnostics.
|
$16.29B |
$178.18
+1.67%
|
|
ICLR
ICON Public Limited Company
Directly describes ICON's outsourced drug development and management services as a Contract Research Organization.
|
$15.16B |
$183.68
+5.24%
|
|
NBIX
Neurocrine Biosciences, Inc.
Neurocrine's core focus is neuroscience with programs in neuropsychiatric disorders (MDD, schizophrenia, TD) and related CNS conditions.
|
$15.03B |
$151.56
+5.60%
|
|
RVMD
Revolution Medicines, Inc.
Clinical-stage biotech focused on oncology; primary products are RAS(ON) inhibitors for cancer.
|
$14.50B |
$77.53
+1.58%
|
|
ROIV
Roivant Sciences Ltd.
Immunovant's FcRn-targeting therapies (e.g., IMVT-1402, batoclimab) are monoclonal antibody therapeutics.
|
$14.25B |
$20.86
+0.02%
|
|
BBIO
BridgeBio Pharma, Inc.
Attruby (acoramidis) and other BridgeBio pipeline assets are oral small-molecule therapeutics, covering multiple rare genetic diseases.
|
$13.71B |
$71.71
+1.53%
|
|
GH
Guardant Health, Inc.
Companion diagnostics: Guardant's tests serve as companion diagnostics for cancer therapies.
|
$13.44B |
$107.80
-0.93%
|
|
MDGL
Madrigal Pharmaceuticals, Inc.
Rezdiffra is an oral, small-molecule therapeutic (THR-β agonist) approved for MASH, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$13.40B |
$601.25
+1.56%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is a PD-1/VEGF bispecific antibody, placing Summit in the Bispecific Antibodies investable theme.
|
$13.24B |
$17.83
+1.08%
|
|
IONS
Ionis Pharmaceuticals, Inc.
Ionis's core platform is RNA-targeted antisense oligonucleotides, directly aligning with the Oligonucleotide Therapeutics category.
|
$13.18B |
$82.70
+2.19%
|
|
OKLO
Oklo Inc.
Atomic Alchemy's production of high-value radioisotopes for medical, industrial, defense, and AI applications aligns with radiopharmaceuticals.
|
$13.10B |
$88.77
+3.49%
|
|
VTRS
Viatris Inc.
Viatris is a large-scale producer of generic medicines and biosimilars, core to its business.
|
$12.40B |
$10.64
+0.80%
|
|
ASND
Ascendis Pharma A/S
Ascendis Pharma focuses on rare-disease endocrinology therapies (YORVIPATH, SKYTROFA, TransCon CNP) within biotech, fitting the Biotech - Rare Diseases category.
|
$12.08B |
$210.41
+1.82%
|
|
EXEL
Exelixis, Inc.
Exelixis is a biotech company focused on oncology therapies, including cabozantinib (CABOMETYX) and pipeline assets.
|
$11.90B |
$44.21
+2.50%
|
|
RDY
Dr. Reddy's Laboratories Limited
Significant emphasis on biosimilar development and commercialization.
|
$11.67B |
$13.98
+0.76%
|
|
ELAN
Elanco Animal Health Incorporated
Vaccines are a major product category and a focus of Elanco's innovation pipeline.
|
$11.58B |
$23.32
-0.49%
|
|
QGEN
Qiagen N.V.
QIAstat-Dx serves as companion diagnostics in pharma collaborations, aligning with the Companion Diagnostics tag.
|
$10.77B |
$48.10
-0.95%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a bispecific antibody, a core oncology modality represented by Bispecific Antibodies.
|
$10.73B |
$176.95
-1.72%
|
|
BMRN
BioMarin Pharmaceutical Inc.
BioMarin's core commercial therapies (VOXZOGO for skeletal disorders and enzyme replacement therapies like PALYNZIQ, VIMIZIM, NAGLAZYME) are all in the rare diseases space, fitting the Biotech - Rare Diseases investable theme.
|
$10.66B |
$55.48
-1.44%
|
|
TECH
Bio-Techne Corporation
Bio-Techne's core business includes recombinant proteins and enzymes used as highly characterized reagents across life-science workflows.
|
$10.05B |
$64.60
-1.90%
|
|
MRNA
Moderna, Inc.
Direct vaccines products (Spikevax and pipeline vaccines) are Moderna's core revenue drivers and product line.
|
$9.73B |
$25.00
+1.03%
|
|
BAX
Baxter International Inc.
Pharmaceuticals segment aligns with Large Cap Pharma as Baxter pursues new product launches.
|
$9.71B |
$18.91
+1.31%
|
|
RNA
Avidity Biosciences, Inc.
Direct product modality: oligonucleotide therapeutics (AOC platform) delivering RNA payloads.
|
$9.21B |
$71.58
+0.03%
|
|
VRNA
Verona Pharma plc
Verona's Ohtuvayre (ensifentrine) is a small-molecule therapeutic used for COPD management.
|
$9.10B |
$106.91
|
|
BIO
Bio-Rad Laboratories, Inc.
Bio-Rad's Saber Bio antibody discovery platform represents a dedicated platform for high-throughput antibody and T cell receptor discovery.
|
$8.85B |
$327.17
-1.52%
|
|
CRL
Charles River Laboratories International, Inc.
CRL operates as a contract research organization, outsourcing preclinical drug development services.
|
$8.81B |
$178.98
+0.52%
|
|
HIMS
Hims & Hers Health, Inc.
Peptide therapeutics manufacturing and development capabilities.
|
$8.68B |
$38.41
+3.55%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme's ENHANZE is a proprietary drug-delivery platform enabling rapid, subcutaneous administration of large-volume biologics.
|
$8.50B |
$72.68
-0.19%
|
|
CORT
Corcept Therapeutics Incorporated
Corcept develops and commercializes oral small-molecule cortisol modulators (Korlym, relacorilant) for hypercortisolism and oncology, fitting 'Oral Small Molecule Therapeutics'.
|
$8.41B |
$79.83
-0.56%
|
|
BPMC
Blueprint Medicines Corporation
AYVAKIT is Blueprint Medicines' flagship oncology/hematology drug; directly produced and marketed, fitting Biotech - Oncology.
|
$8.27B |
$129.46
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.16B |
$123.82
+0.31%
|
Showing page 3 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
